Langer, Ciechanover god­fa­ther the lat­est AI up­start; Ipsen forges $446M AML de­vel­op­ment pact

There’s a new AI play­er jump­ing in­to the drug dis­cov­ery game. And they have some high-pow­ered sci­en­tif­ic ad­vi­sors in their cor­ner.

Tel Aviv-based Quris has built what it calls a “pa­tient-on-a-chip” AI plat­form that it’s tout­ing as a way to cir­cum­vent un­re­li­able an­i­mal test­ing with a more ef­fi­cient way to judge safe­ty and ef­fi­ca­cy. An­i­mal test­ing, par­tic­u­lar­ly in­volv­ing mice, has proven a no­to­ri­ous­ly un­re­li­able way to do pre­clin­i­cal test­ing — though it is well-es­tab­lished with reg­u­la­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.